AZTherapies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aztherapies.com
Clinical Trials
9
Active:4
Completed:3
Trial Phases
3 Phases
Phase 1:6
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (66.7%)Phase 2
2 (22.2%)Phase 3
1 (11.1%)Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers
Phase 1
Completed
- Conditions
- Alzheimer DiseaseHealthy Volunteers
- Interventions
- Drug: ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen)
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- AZTherapies, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04570644
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
Phase 2
Terminated
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Drug: ALZT-OP1a (cromolyn)
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- AZTherapies, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04428775
- Locations
- 🇺🇸
UCSD Altman Clinical and Translational Research Institute, La Jolla, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Hospital for Special Surgery, New York, New York, United States
Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)
Phase 2
Withdrawn
- Conditions
- Ischemic StrokePost-stroke Cognitive Impairment
- Interventions
- Other: Placebo
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- AZTherapies, Inc.
- Registration Number
- NCT03202147
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
Phase 3
Completed
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2021-11-10
- Lead Sponsor
- AZTherapies, Inc.
- Target Recruit Count
- 620
- Registration Number
- NCT02547818
- Locations
- 🇺🇸
Cognitive Clinical Trials, Omaha, Nebraska, United States
🇺🇸Xenoscience, Phoenix, Arizona, United States
🇺🇸Territory Neurology & Research Institute, Tucson, Arizona, United States
Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- AZTherapies, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT02482324
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
News
No news found